| Genomic and transcriptional aberrations linked to breast cancer pathophysiologies K Chin, S DeVries, J Fridlyand, PT Spellman, R Roydasgupta, WL Kuo, ... Cancer cell 10 (6), 529-541, 2006 | 1451 | 2006 |
| Whole-genome analysis informs breast cancer response to aromatase inhibition MJ Ellis, L Ding, D Shen, J Luo, VJ Suman, JW Wallis, BA Van Tine, ... Nature 486 (7403), 353-360, 2012 | 1153 | 2012 |
| Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A … JS Vaidya, F Wenz, M Bulsara, JS Tobias, DJ Joseph, M Keshtgar, ... The Lancet 383 (9917), 603-613, 2014 | 902 | 2014 |
| Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial JS Vaidya, DJ Joseph, JS Tobias, M Bulsara, F Wenz, C Saunders, ... The Lancet 376 (9735), 91-102, 2010 | 877 | 2010 |
| Rethinking screening for breast cancer and prostate cancer L Esserman, Y Shieh, I Thompson Jama 302 (15), 1685-1692, 2009 | 675 | 2009 |
| Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. JL Khatcheressian, P Hurley, E Bantug, LJ Esserman, E Grunfeld, ... | 669 | 2012 |
| Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–rich stage 2 to 3 breast cancer … MJ Ellis, VJ Suman, J Hoog, L Lin, J Snider, A Prat, JS Parker, J Luo, ... Journal of clinical oncology 29 (17), 2342, 2011 | 623 | 2011 |
| A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ... Jama 305 (18), 1873-1881, 2011 | 619 | 2011 |
| Overdiagnosis and overtreatment in cancer: an opportunity for improvement LJ Esserman, IM Thompson, B Reid Jama 310 (8), 797-798, 2013 | 593 | 2013 |
| Adaptive randomization of veliparib–carboplatin treatment in breast cancer HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ... New England Journal of Medicine 375 (1), 23-34, 2016 | 550 | 2016 |
| Addressing overdiagnosis and overtreatment in cancer: a prescription for change LJ Esserman, IM Thompson, B Reid, P Nelson, DF Ransohoff, HG Welch, ... The lancet oncology 15 (6), e234-e242, 2014 | 535 | 2014 |
| Leukocyte composition of human breast cancer B Ruffell, A Au, HS Rugo, LJ Esserman, ES Hwang, LM Coussens Proceedings of the National Academy of Sciences 109 (8), 2796-2801, 2012 | 520 | 2012 |
| Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging L Esserman, N Hylton, L Yassa, J Barclay, S Frankel, E Sickles Journal of clinical oncology 17 (1), 110-110, 1999 | 507 | 1999 |
| Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657/I-SPY TRIAL NM Hylton, JD Blume, WK Bernreuter, ED Pisano, MA Rosen, EA Morris, ... Radiology 263 (3), 663-672, 2012 | 487 | 2012 |
| Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657 LJ Esserman, DA Berry, A DeMichele, L Carey, SE Davis, M Buxton, ... Journal of Clinical Oncology 30 (26), 3242, 2012 | 473 | 2012 |
| Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively … R Nanda, MC Liu, C Yau, R Shatsky, L Pusztai, A Wallace, AJ Chien, ... JAMA oncology 6 (5), 676-684, 2020 | 443 | 2020 |
| Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy SC Partridge, JE Gibbs, Y Lu, LJ Esserman, D Sudilovsky, NM Hylton American Journal of Roentgenology 179 (5), 1193-1199, 2002 | 401 | 2002 |
| Breast cancer growth prevention by statins MJ Campbell, LJ Esserman, Y Zhou, M Shoemaker, M Lobo, E Borman, ... Cancer research 66 (17), 8707-8714, 2006 | 399 | 2006 |
| MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition D Horiuchi, L Kusdra, NE Huskey, S Chandriani, ME Lenburg, ... Journal of Experimental Medicine 209 (4), 679-696, 2012 | 367 | 2012 |
| Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) LJ Esserman, DA Berry, MCU Cheang, C Yau, CM Perou, L Carey, ... Breast cancer research and treatment 132, 1049-1062, 2012 | 364 | 2012 |
